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Vancomycin, one of few effective treatments against methicillin-
resistant Staphylococcus aureus, is nephrotoxic. The goals of this
study were to (1) gain insights into molecular mechanisms
of nephrotoxicity at the genomic level, (2) evaluate gene markers
of vancomycin-induced kidney injury, and (3) compare gene
expression responses after iv and ip administration. Groups of six
female BALB/c mice were treated with seven daily iv or ip doses of
vancomycin(50,200,and400mg/kg)orsaline,andsacriﬁcedonday
8. Clinical chemistry and histopathology demonstrated kidney
injury at 400 mg/kg only. Hierarchical clustering analysis revealed
thatkidneygeneexpressionproﬁlesofallmicetreatedat400mg/kg
clustered with those of mice administered 200 mg/kg iv. Transcrip-
tional proﬁling might thus be more sensitive than current clinical
markersfordetectingkidneydamage,thoughtheproﬁlescandiffer
with the route of administration. Analysis of transcripts whose
expression was changed by at least twofold compared with vehicle
saline after high iv and ip doses of vancomycin suggested the
possibility of oxidative stress and mitochondrial damage in
vancomycin-inducedtoxicity.Inaddition,ourdatashowedchanges
in expression of several transcripts from the complement and
inﬂammatory pathways. Such expression changes were conﬁrmed
by relative real-time reverse transcription–polymerase chain re-
action. Finally, our results further substantiate the use of gene
markers of kidney toxicity such as KIM-1/Havcr1, as indicators of
renal injury.
Key Words: vancomycin; route of administration;
nephrotoxicity; gene expression; inﬂammation; complement
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As the body compartment responsible for concentration and
excretion of toxic metabolites and drugs, kidney is a frequent
site of drug toxicity. Nephrotoxicity contributes to 8–60% of
all cases of in-hospital acute kidney injury (Schetz et al., 2005).
When assessing nephrotoxicity, the tubular secretion system,
which allows transport of the drug from the blood to the urine
via the tubular cells, is particularly important (Fanos et al.,
2001). The biomarkers currently used clinically to assess
nephrotoxicity are primarily changes in the level of blood urea
nitrogen (BUN) and serum creatinine (CRE) (Duarte et al.,
1993). However, such changes are only measurable after 30–
50% of ﬁnal tissue damage has occurred (Duarte et al., 1993),
emphasizing the critical need for more sensitive marker(s) to
detect kidney injury.
Glycopeptide antibiotics, such as vancomycin, teicoplanin,
ramoplanin, and decaplanin, are glycosylated cyclic or poly-
cyclic nonribosomal peptides. Because of their toxicity, their
use is restricted to patients who are critically ill or who have
a demonstrated hypersensitivity to the b-lactams. Vancomycin
is one of the last available lines of defense against the Gram-
positive bacterium methicillin-resistant Staphylococcus aureus
(MRSA). After iv administration, however, nephrotoxicity has
been reported in 7–17% of patients (Downs et al., 1989; Eng
et al., 1989; Mellor et al., 1985). Vancomycin-induced renal
damage requires energy-dependent transport from the blood
to the tubular cells across the basolateral membrane (Fanos et al.,
2001). In the tubular cells, vancomycin presents a pronounced
lysosomal tropism (Fanos et al., 2001). Animal studies sug-
gested oxidative stress might underlie the pathogenesis of
vancomycin-induced toxicity (Nishino et al., 2003; Oktem et al.,
2005). Despite this information, the mechanisms of vancomycin
toxicity remain poorly understood, and a better appreciation of
these mechanisms would be useful in designing strategies to
prevent it. Our study was intended to uncover potential
mechanisms of vancomycin toxicity at the genomic level.
Toxicogenomics, gene expression analysis applied to
toxicology, is actively being employed in drug discovery. It
is used as a screening tool to rapidly identify signs of toxicity
associated with lead compounds and to understand mechanisms
of chemical toxicity and action; this use is possible because
compounds belonging to a single class of toxicants yield
similar gene expression patterns that are distinct from other
proﬁles generated by other classes of chemicals (Bartosiewicz
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the cells of target organs can give indications of the biological
and biochemical mechanisms affected by a pharmaceutical
compound (Ganter et al., 2005). Similarly, several research
groups have attempted to identify potential biomarkers and
signature proﬁles of toxicity for various organs (Merrick et al.,
2004), especially for kidneys (Amin et al., 2004; Thukral et al.,
2005). The Thukral studies, performed in rats after ip
administration of various drugs, identiﬁed several candidate
genes modulated in a dose- and time-dependent manner in
response to injury. They included kidney molecule injury
(KIM-1/Havcr1), osteopontin (Spp1), ﬁbrinogen alpha poly-
peptide (Fga), insulin-like growth factor binding protein 1
(Igfbp1), glutathione S-transferase cluster (Gsta), clusterin
(Clu), lipocalin 2 (Lcn2), and several transporters. Some of
these markers, including Clu, Spp1, and Havcr1, were also
conﬁrmed in a nonhuman primate model of antibiotic-induced
nephrotoxicity (Davis et al., 2004), suggesting that such
markers are not restricted to rodent animal models and may be
relevant to human applications.
In the study described herein, we have performed gene
expression proﬁling on the kidney of mice administered various
doses of vancomycin either iv or ip. The goals were to (1) gain
insights into the molecular mechanisms of vancomycin-induced
nephrotoxicity, (2) identify potential markers of renal toxicity,
and (3) compare the gene expression responses after iv and ip
delivery to identify potential differences between the two most
common routes of administration in humans (iv) and in animal
models (ip).
MATERIALS AND METHODS
Animals
Female BALB/c mice (Charles River Laboratories, Inc., Wilmington, MA),
6–8 weeks old, were maintained on Purina Certiﬁed Rodent Chow 5002
(Richmond, IN) and puriﬁed tap water ad libitum in microisolator cages under
controlled lighting (12-h light/dark cycle). All animals were treated in
accordance with a protocol approved by the Institutional Animal Care and
Use Committee.
Experimental Designs
For the toxicity study (microarray analysis, clinical pathology, and
histology), groups of six mice were administered vancomycin (Sigma,
St Louis, MO) at 50, 200, or 400 mg/kg daily for 7 consecutive days; the
doses were delivered iv or ip (iv-50, iv-200, iv-400, ip-50, ip-200, and ip-400).
Control mice were administered a similar volume of 0.9% saline solution by
both routes (iv-0 and ip-0, six mice per group). Clinical observations were
recorded daily, and body weights were measured on days 1, 3, 5, and 8. Mice
were sacriﬁced on day 8, 24 h after the last vancomycin treatment.
For the toxicokinetic (TK) analysis, groups of 12 mice were administered iv
or ip vancomycin at 50, 200, and 400 mg/kg. Five control mice remained
untreated.
Sample Collection
For microarray analysis, mice were sacriﬁced on day 8, 24 h after the last of
seven daily doses of vancomycin. The left kidney of each mouse was removed
and immediately placed into 1.8 ml of RNAlater (Qiagen, Valencia, CA). After
overnight incubation at room temperature, each kidney was transferred into
a new tube and immediately stored at  80 C until it was processed for RNA
extraction.
For clinical pathology, blood samples were collected from the retro-orbital
sinus on day 3 (prior to administration of the third dose) and day 8 (prior to
sacriﬁce). Within each experimental group (six mice), the blood from three
mice was collected for clinical chemistry analysis.
For histological analysis, tissues were removed from the animal immediately
after sacriﬁce and placed directly into 10% neutral buffered formalin.
For TK analysis, blood samples were collected, with ethylenediaminetetra-
acetic acid as anticoagulant, from the retro-orbital sinuses of three mice per
group at 0.083, 0.25, 0.5, 1, 2, 4, 6, and 24 h after the ﬁrst and the seventh dose
administration. Because some animals were found moribund or dead in the iv
high-dose group, samples for that particular group were collected at only four
time points (0.083, 0.5, 1, and 4 h). Within 15 min of collection, blood samples
were centrifuged for plasma collection and subsequently stored at  80 C until
analysis.
Plasma Concentration of Vancomycin and TK Analysis
Vancomycin was extracted from mouse plasma by solid phase extraction
(SPE) based on the protocol described by Farin and colleagues (Farin et al.,
1998). Solid phase Oasis HLB C18 microelution plates (Waters, Inc., Milford,
MA) were preconditioned with 1 ml methanol followed by 1 ml water. After
50 ll of plasma and 50 llo f2 0lg/ml tinidazole (internal standard) were drawn
through the wells of the SPE plate, each well was washed with 0.5 ml of water,
followed by 0.5 ml of 5% methanol. Vancomycin and tinidazole were eluted
from the SPE plate with 0.6 ml of 1:1 (v:v) acetonitrile:50mM KH2PO4 (pH 4).
The solvents were removed under a nitrogen ﬂow without heat application, and
the dry residues were reconstituted in 100 ll of water. The plate was
centrifuged (425 3 g, 15 min) prior to high-pressure liquid chromatography
(HPLC) analysis. Study samples were quantitated using a set of calibration
standards (0.5, 2.5, 5, 10, 25, 50, and 100 lg/ml) prepared in blank matrix and
processed simultaneously.
Samples were analyzed by HPLC with detection by ultraviolet absorbance at
282 nm. Samples (50 ll) were injected onto a Luna C8 column (4.6 3 100 mm;
5 l; Phenomenex, Torrance, CA) and eluted at a ﬂow rate of 1.5 ml/min with
the following gradient conditions: mobile phase A ¼ 5mM KH2PO4, pH 2.8,
and mobile phase B ¼ acetonitrile; 0 and 1.5 min: 97% A, 3% B; 11.5 and 14
min: 80% A, 20% B; 15 and 20 min: 97% A, 3% B.
Under these conditions, vancomycin and tinidazole eluted at 5.9 and 7.5
min, respectively. A calibration standard curve was prepared by performing
weighted linear regression (1/y) of the peak area ratio of vancomycin/tinidazole
versus the concentration of vancomycin.
TK Analysis
ThemeasuredplasmalevelsweresubjectedtononcompartmentalTKanalysis
using WinNonlin software version 5.0 (PharSight Corp., Mountain View, CA).
The TK values reported are the maximal plasma concentration (Cmax), the time
to reach the Cmax (Tmax), and the area under the plasma concentration versus
time curve (AUC
0/
N). Bioavailability (F) after ip administration was
calculated using the formula: (AUCip/AUCiv) 3 (Doseiv/Doseip).
Clinical Chemistry
After collection at SRI International, serum samples were sent to IDEXX
Veterinary Services, Inc. (West Sacramento, CA) for clinical chemistry
parameter evaluation.
Histopathology
Tissues retained in 10% neutral buffered formalin were subsequently
embedded into parafﬁn, cut approximately 5 lm thick, and stained with
hematoxylin and eosin (H&E). Histopathologic examination was performed by
a board-certiﬁed veterinary pathologist (D. Fairchild, SRI International).
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Total RNA isolation. Approximately 15–20 mg of each of the 48 kidneys
were transferred into 1 ml of Trizol reagent (Invitrogen, Carlsbad, CA) along
with a stainless steel bead (Qiagen), and homogenized with a TissueLyser
(Qiagen). Total RNA was extracted with 200 ll of chloroform, precipitated
with 500 ll of 100% ethanol, and transferred to an RNeasy mini spin column
(Qiagen) for puriﬁcation according to the manufacturer’s instructions. Total
RNA was subsequently precipitated with ethanol, resuspended in water, and
stored at  70 C. RNA integrity was examined by agarose gel electrophoresis
and spectrophotometric analysis.
Affymetrix GeneChip protocols. cDNA was prepared and cleaned from
10 lg total RNA using the One-Cycle cDNA Synthesis and Clean-up module
kits (Affymetrix, Santa Clara, CA). The cDNA was further processed to biotin-
labeled cRNA using the IVT labeling kit (Affymetrix). The cRNA was
fragmented before hybridization to the GeneChip Mouse Genome 430 2.0
Array (Affymetrix) and scanning (TGT value ¼ 500). All procedures were
performed according to the manufacturer’s instructions, as described in the
Affymetrix Genechip Expression Analysis Technical Manual, revision 5 (http://
www.affymetrix.com/support/technical/manual/expression_manual.affx).
Data analysis. The Affymetrix CEL ﬁles were loaded into GeneSpring
GX version 7.3.1 (Agilent Technologies, Santa Clara, CA) and preprocessed
using GenChip Robust Multi-Array analysis (GC-RMA) (Wu et al., 2004). In
GeneSpring GX, an experiment was created, consisting of 48 kidney samples
(six mice per group and eight experimental conditions) represented by 48 arrays
and a per-gene normalization to the median was applied. A total of 9502 probes
(subsequently referred to as the ‘‘probe list’’) were selected for further analysis
from the 45,101 original probes by performing two successive levels of
ﬁltering. First, probes with a raw intensity value > 60 in 5/8 conditions were
selected to eliminate those with an intensity value close to background levels.
Second, a one-way ANOVA was performed using a parametric test assuming
equal variances and Benjamini and Hochberg as multiple testing corrections
with a False Discovery Rate ¼ 0.01. This ANOVA analysis was used to select
genes that were signiﬁcantly differentially expressed in at least one of the
pairwise comparisons (group-to-group comparisons of the 8 experimental
groups), ensuring that the differences were due to the treatment, not due to
chance; it also ﬁltered out genes without any changes across all of the
experimental conditions. All subsequent analysis performed using the above
probe list employed the averaged intensity value of each gene within each
experimental condition (geometric mean of the six samples for each
experimental condition).
The data discussed in this publication have been deposited at the National
Center for Biotechnology Information Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/). They are accessible through GEO Series
accession number GSE7793.
Real-Time Relative Reverse Transcription–Polymerase Chain Reaction
Total RNA (5 lg) isolated as previously described was submitted to cDNA
synthesis using a High Capacity cDNA reverse transcription kit (Applied
Biosystems [ABI], Foster City, CA). Of the resulting cDNA, 38 ng was
subjected to reverse transcription–polymerase chain reaction (RT-PCR) using
the Taqman expression assays (ABI) for Gapdh, Spp1, Havcr1, C3, C4b,
Cxcl1, and Rtn4 according to the manufacturer’s instructions. PCR was
performed with a LightCyler 480 (Roche Applied Science, Indianapolis, IN)
using the following conditions: 1 cycle of 10 min at 95 C, and 40 cycles of 10 s
at 95 C and 30 s at 60 C. For each experimental group, three samples,
manually selected at random were analyzed, and each sample was measured in
duplicate. Fold change expression was evaluated relative to the appropriate
control samples (iv or ip administration of saline) using the comparative CT
method (Livak et al., 2001).
Statistical Analysis
Multiple group (> 3) comparisons (clinical pathology and organ weight
data) were performed separately on the iv and ip treated samples using one-way
ANOVA with Dunnett’s multiple comparison test. The appropriate saline
treated animals (ip-0 or iv-0) were used as controls.
RESULTS
Toxicokinetic Analysis
Although vancomycin is administered iv in humans, most of
the published vancomycin studies in animal models are done
through ip injection. We compared the efﬁciency of the iv and
ip routes in delivering vancomycin into systemic circulation
after administration of one and seven doses of vancomycin at
50, 200, and 400 mg/kg. Analysis of the TK parameters (Table 1)
revealed that peak vancomycin concentrations (Cmax) after iv
administration were consistently higher than those measured
after ip administration. The largest difference in Cmax value
(3.4-fold) between iv and ip administration was observed
after seven doses of vancomycin at 200 mg/kg (Cmax of 489
and 145 lg/ml, respectively). In addition, for the 200 and
400 mg/kg doses, the Cmax was reached (Tmax) more rapidly
after iv administration than after ip administration (0.083 vs.
0.5 h). At the 200 mg/kg dose level, the AUC
0/N after iv dose
administration is larger than the AUC
0/N after ip administra-
tion. In contrast, at the 400 mg/kg dose level, the AUC
0/N
after ip administration was higher than that after iv adminis-
tration (2.4- and 1.6-fold greater after one and seven injec-
tions, respectively). These results suggested that the route of
administration has a major impact on the TK parameters.
Clinical Chemistry
Blood samples were collected on day 3 and day 8, after two
and seven vancomycin injections, respectively, to evaluate 17
TABLE 1
TK Parameters after Injection of One and Seven Doses of
Vancomycin
Dose
(mg/kg) Route Day
Cmax
(lg/ml) Tmax (h)
AUC
0/N
(lg h/ml) F (%)
50 iv 1 108 0.083 51
50 ip 1 43 0.25 51 100
50 iv 7 93 0.083 46
50 ip 7 46 0.25 46 100
200 iv 1 417 0.083 328
200 ip 1 161 0.50 254 77
200 iv 7 489 0.083 369
200 ip 7 145 0.50 211 57
400 iv 1 787 0.083 1927
400 ip 1 435 0.50 4708 244
400 iv 7 940 0.083 2439
400 ip 7 650 0.50 4033 165
Note. Cmax: peak serum concentration; Tmax: time when the peak serum
concentration is reached; AUC
0/N: area under the plasma concentration versus
time curve. F: bioavailability after ip administration.
260 DIETERICH ET AL.chemistry parameters. Most of the variations occurred only on
day 8; the most important signiﬁcant (p < 0.05) changes are
presented in Figure 1. These changes occurred mainly after
administration of high-dose vancomycin. There was a statisti-
cally signiﬁcant increase in BUN after iv administration only,
although there was a trend toward increased BUN values after
ip treatment as well. Other parameters, such as alkaline
phosphatase (ALP) and gamma-glutamyl transferase (GGT),
were also affected by high-dose vancomycin treatment. We
also observed a slight, but statistically signiﬁcant (p < 0.05),
increase in globulin (3 ± 0.2 and 3 ± 1 g/dl compared to 2 ± 0.1
and 2 ± 0.3 g/dl after iv and ip administration, respectively) and
a decrease in total protein (6 ± 0.2 and 6 ± 0.6 g/dl compared to
5 ± 0.2 and 5 ± 0.4 g/dl after iv and ip administration,
respectively; data not shown). CRE levels, however, were not
signiﬁcantly affected by vancomycin administration (data not
shown), probably because such changes only take place when
30–50% of tissue damage has occurred (Duarte et al., 1993).
These results suggest that high-dose vancomycin was
responsible for almost all detectable signs of toxicity and that
the drug’s primary effects are on kidney and liver function.
Renal Histopathology
Microscopic evaluations were performed on the following
tissues from BALB/c mice given saline and 400 mg/kg
vancomycin: right kidney, liver caudal lobe, gross lesions
(including tissue masses and abnormal regional lymph nodes),
lungs with bronchi, injection site, spleen, stomach, and
duodenum, small intestine (ileum, cecum, and colon), urinary
bladder, mesenteric lymph nodes, heart, and adrenal glands.
Kidney and liver were also evaluated in tissues from the
medium (200 mg/kg) dose groups. Signiﬁcant alterations were
observed only in kidney tissues.
Representative sections of the proximal tubules in control
and high-dose treated animals are shown in Figure 2. The
primary ﬁnding in kidneys of mice given vancomycin at 400
mg/kg either iv or ip was proximal tubular necrosis (A),
characterized by necrosis of proximal tubular cells, protein
droplets and cellular debris within proximal tubular lumens,
and stretching of tubular cells caused by loss of epithelial cells.
We also observed regeneration of cuboidal cells of the
proximal tubules (B). Inﬂammatory cell inﬁltration into the
affected renal tissue was minimal.
Transcriptional Response in the Kidney
Overview of the host transcriptional response after vanco-
mycin administration. The 9502 probes from the probe list
(see Materials and Methods) were submitted to hierarchical
clustering analysis (Pearson correlation and average linkage
clustering) using the average intensity value of the six samples
in each experimental group (Fig. 3). This analysis revealed two
distinct nodes: the iv-400, iv-200, and ip-400 groups fell within
the ﬁrst node, and the remaining treatment groups (iv-0, iv-50,
ip-0, ip-50, and ip-200) fell within the second major node. The
ﬁnding that samples from the iv-200 group clustered with
the high-dose treatment samples was surprising because, unlike
the iv-400 and ip-400 mice, iv-200 animals did not exhibit signs
oftoxicityinclinical chemistryand histopathology assessments.
This ﬁnding suggests that an iv dose of 200 mg/kg might induce
toxicity identiﬁable with gene expression proﬁles even though it
is not clinically detectable. It is interesting to observe that the
host transcriptional response can differ depending on the route
of administration.
To investigate the difference between the ip and iv routes of
administration in greater detail, we performed one-way
ANOVA analyses (parametric test assuming equal variances,
Benjamini and Hochberg as multiple testing corrections with
a False Discovery Rate ¼ 0.01, and Tukey post hoc test) to
FIG. 1. Serum clinical chemistry analysis. Groups of six BALB/c mice
were administered daily doses (50, 200, and 400 mg/kg) of vancomycin either
iv or ip for 7 consecutive days. Control mice were given a similar volume of
saline solution (0). On day 8, blood from three randomly selected mice per
group was collected, and serum levels of BUN, ALP, and GGT were assessed.
Results of each individual measurement are represented as well as the mean
value. *p < 0.05, as determined by one-way ANOVA with Dunnett’s multiple
comparison post-test.
VANCOMYCIN TOXICITY ASSESSED BY MICROARRAY 261identify how many probes were signiﬁcantly differentially
expressed between each dose group (50, 200, and 400 mg/kg)
and the control (saline). Two independent analyses were
performed, one using the samples from the iv route and one
using the samples from the ip route. The results, presented in
Table 2, conﬁrmed that the two routes led to different host
transcriptional proﬁles. After administration of low or medium
doses, a larger number of probes (7 and 16 times more for 50
and 200 mg/kg, respectively) presented a signiﬁcantly different
intensity value compared to control animals after iv adminis-
tration compared to ip (119 vs. 17 and 707 vs. 43 probes,
respectively). The changes in gene expression were linked to
thesystemicexposureofvancomycininmice(Table1):onday7,
the drug levels in plasma were higher after iv administration at
low and medium doses. For administration of a high dose of
vancomycin, delivery via the ip route induced slightly more
changes (1.5 times more; 6,763 vs. 4,347 probes) compared to
the iv route. This ﬁnding is consistent with the pharmacokinetic
evaluationinTable1,whichshowsthattheAUC
0/Nwashigher
after ip administration of 400 mg/kg vancomycin than
the AUC
0/N after iv administration. These results suggest that
the differences in gene expression proﬁle are likely to reﬂect a
difference in drug exposure.
Predominant changes in the kidney after high-dose
vancomycin administration, independent of the route of
administration. To analyze the most predominant gene
expression changes associated with vancomycin treatment,
we selected, from the probe list the elements presenting
a greater than twofold change in intensity between iv-400 and
iv-0 and between ip-400 and ip-0. This analysis identiﬁed 1537
probes composed of 53% (818/1537) downregulated and 47%
(719/1537) upregulated elements. To uncover the biological
themes associated with these 1537 probes, we extracted the
FIG. 2. Histopathological evidence of vancomycin nephrotoxicity. BALB/c mice were treated as described in Figure 1. Approximately, 24 h after the seventh
vancomycin infection, the right kidney of each mouse was collected in 10% neutral buffered formalin, embedded into parafﬁn, and cut approximately 5 lm thick.
Representative H&E-stained sections of control and high-dose treated animals (vancomycin at 400 mg/kg) are shown. The letters A and B point to a necrotic tubule
and a regenerative proximal tubule, respectively.
FIG. 3. Hierarchical clustering of vancomycin-treated kidney samples. The
average (n ¼ 6) normalized intensity value of the 9502 probes from the probe
list across all the experimental conditions was represented in green (down-
regulation), red (upregulation), and black (insigniﬁcant changes) on the y-axis.
Experimental conditions (iv and ip administration of saline [0 mg/kg] and 50,
200, and 400 mg/kg vancomycin) are plotted on the x-axis.
TABLE 2
One-Way ANOVA Analysis Indicating Number of Probes
Changing after Each Experimental Condition compared with
their Respective Controls (Evaluation Performed on Day 8)
Dose vancomycin (mg/kg)
Route
Common probes iv ip
50 119 17 0
200 707 43 8
400 4347 6,763 3746
262 DIETERICH ET AL.gene ontology (GO) terms with EASE, a program for
calculating the statistical enrichment of GO annotations
(Hosack et al., 2003). GO is a hierarchical, structured
vocabulary that describes gene products in terms of their
biological process, cellular component, and molecular function
(Ashburner et al., 2000). Using the Affymetrix mouse 430_2 as
a background list and high classiﬁcation stringency, we
identiﬁed several clusters and selected the ones presenting an
enrichment score greater than 4 (Table 3).
Among the 818 downregulated probes (Supplementary
Table 1), seven clusters presented an enrichment score >
4 (Table 3). The predominant changes affected genes involved
in metabolism/catabolism of amine, amino acid, and nitrogen
compounds. Among the downregulated genes, a large number
of transport-related genes (Slc14a2, Slc38a2, Slc39a14,
Slc39a6, Slc41a2, Slc44a1, Slc44a2, Slc44a3, Slc7a1, Slco3a1,
Aqp11, and Kcnk1) and several mitochondrial genes (Acad9,
Acad10, Acad11, Acadsb, Car5a, Bcat2, Acaa2, Shmt2, and
Sod2) were signiﬁcantly enriched. These results suggest that
vancomycin treatment altered the overall metabolic activity of
the kidney. More speciﬁcally, it affected the function
(reabsorption) of the proximal tubule cells and of their
energy-producing mitochondria.
Among the 719 upregulated probes (Supplementary Table 2),
two clusters presented an enrichment score > 4 (Table 3).
The most enriched cluster (cluster #1, enrichment score 16.87)
consisted of genes involved in immune response/defense,
mainly several histcompatibility 2 genes (H2), several
components of the complement pathway (C4b, C3, C1qa,
Cﬁ, C1r, C1s, Cfh, and C1qb) and the proteasome (Psme1,
Psme2, Psmb9, and Psmb8), as well as chemokines (Cxcl16)
and interferon-related genes (Irf1, Irf8, Iﬁtm1, If203, Iﬁ205,
Iﬁ27, Iﬁ35, Iﬁtm3, Mpa2l, and Iﬁt2). These results suggest that
inﬂammation and complement activation might be involved in
vancomycin-induced pathogenesis, as they are in renal ischemia/
reperfusion (I/R) (Thurman, 2007). Because adhesion molecules
also participate in the kidney injury after I/R (Thurman, 2007),
we evaluated the expression proﬁle of intracellular adhesion
molecule (Icam1), E-selectin (Sele), and P-selectin (Selp)a f t e r
vancomycin treatment. Only Icam1 was present in the probe list,
and its expression was upregulated after iv and ip administration
of vancomycin at 400 mg/kg (  8-fold compared to iv-0 or ip-0)
and after iv administration of 200 mg/kg (> 2-fold compared to
iv-0; Supplementary Table 2).
Using relative real-time RT-PCR, we next veriﬁed the
expression of two key components of the complement pathway
(C3 and C4b), as well as expression of the chemokine Cxcl1,
a known early biomarker of ischemic acute renal failure (Molls
et al., 2006). Veriﬁcation was performed on three randomly
selected samples from each experimental group. The results,
presented in Table 4, conﬁrmed the microarray data showing
higher expression of these genes after both iv and ip
administration of vancomycin at 400 mg/kg. None of the
samples from the low dose iv or ip treated animals expressed
TABLE 3
Most Enriched GO Term Categories among the 1537 Probes Whose Intensity Changed by at least Twofold after Administration of
High-Dose Vancomycin compared with Saline, Independently of the Delivery Route (Evaluation Performed on Day 8)
Annotation cluster Enrichment score Number of genes EASE score
a
818 downregulated probes
Cluster #1 16.93 52   1.1E 16
Amino acid and derivative metabolism, nitrogen compound metabolism, amine metabolism, amino acid metabolism
Cluster #2 16.31 22   3.2E 16
Amino acid catabolism, amine catabolism, nitrogen compound catabolism
Cluster #3 8.19 164   1.5E 8
Transport, establishment of localization, localization
Cluster #4 8.09 39   5.4E 6
Organelle inner membrane, mitochondrial inner membrane, mitochondrial membrane, mitochondrial envelope, organelle envelope, envelope, organelle
membrane
Cluster #5 6.24 14   4.7E 7
Amino acid biosynthesis, amine biosynthesis, nitrogen compound biosynthesis
Cluster #6 4.71 24   3.8E 4
Glucose metabolism, hexose metabolism, monosaccharide metabolism, cellular carbohydrate metabolism
Cluster #7 4.03 10   5.3E 3
Pyruvate metabolism, gluconeogenesis, hexose biosynthesis, alcohol bioxynthesis, monosaccharide biosynthesis, carbohydrate biosynthesis
719 upregulated probes
Cluster #1 16.87 76   4.6E 17
Response to biotic stimulus, immune response, defense response
Cluster #2 4.03 12   5.3E 4
Wound healing, blood coagulation, coagulation, hemostatis, regulation of body ﬂuids
aModiﬁed Fisher Exact p value.
VANCOMYCIN TOXICITY ASSESSED BY MICROARRAY 263C3, C4b,o rCxcl1, and only iv administration of vancomycin at
200 mg/kg upregulated expression of these genes.
Speciﬁc changes induced by vancomycin treatment. We
ﬁrst analyzed expression of genes involved in the oxidative
stress response because it was recently suggested to be
a mechanism underlying the pathogenesis of vancomycin-
induced nephrotoxicity (Nishino et al., 2003; Oktem et al.,
2005). In our probe list, we identiﬁed 12 genes that were
involved in reactive oxygen species (ROS) metabolism or
possessed antioxidant properties. The average (n ¼ 6)
expression of these genes differed by at least twofold in
high-dose vancomycin-treated mice compared to control
animals (Table 5). The abundance of most of these transcripts
decreased after high-dose vancomycin treatment, especially
those encoding proteins that belong to the three main cellular
antioxidant groups: superoxide dismutase (Sod2, Sod3),
catalase (Cat), and glutathione peroxidase (Gpx6, Gstk1). In
addition, we observed upregulation of heme oxygenase-1
(Hmox1; Supplementary Table 2 and Fig. 4), which is regarded
as a sensitive and reliable indicator of cellular oxidative stress
(Abraham et al., 2007). Taken together, these results suggested
that vancomycin was inducing an imbalance of the oxidative
stress response globally in favor of decreased ROS elimination.
The expression levels of several genes implicated in the
mechanism(s) of renal toxicity (Amin et al., 2004) in animals
treated with high-dose vancomycin were compared with levels
in animals treated with saline. For this purpose, we selected,
from the probe list, the probes whose expression was
upregulated by at least twofold in iv-400 versus iv-0 or ip-
400 versus ip-0 (data not shown). The resulting list of 2758
probes was chosen to evaluate the vancomycin-induced
genomic changes independent of the route of administration
because of the observation (see Fig. 3) that the iv and ip routes
do not induce similar gene expression proﬁles. Our analysis
revealed that vancomycin treatment modulated the expression
level of several of these previously reported genes (Amin et al.,
2004), including, but not restricted to, hepatitis A virus cellular
receptor 1 (Havcr1; human synonym: KIM-1), Hmox1,
clusterin (Clu), osteopontin/secreted phosphoprotein (Spp1),
and some kallikrein genes (Klk5, Klk6, Klk9, and Klk24).
Figure 4 compares the expression of these markers in iv-400 and
ip-400 samples to expression in their respective control groups.
In most instances, the direction of the change (induction or
repression) was similar to the one reported after cisplatin or
gentamicin treatment (Amin et al., 2004) (data not shown). In
three cases, however (Gc, Idh1,a n dNgfb), vancomycin treatment
induced changes in the opposite direction from treatment with
cisplatin or gentamicin. The results suggest that these three genes
might be vancomycin-speciﬁc in the transcriptional changes
related to kidney damage.
We next undertook to identify new potential biomarkers of
toxicity that exhibited a gradual dose response to vancomycin.
These genes were selected from the probe list based on their
constant increase or decrease in level of expression (at least
1.5-fold) between iv-0 and iv-50, iv-50 and iv-200, and iv-200
and iv-400. The four genes thus identiﬁed were small proline-
rich protein 1A (Sprr1a), AI606844, reticulon 4 (Rtn4), and
ADP-ribosylation factor-like 4D (Arl4d)( S u p p l e m e n t a r yT a b l e2
and unshown data). The relevance of these particular genes in
kidney injury will require further investigation.
The expression of some of the previously described (Spp1,
Havcr1) and herein identiﬁed potential (Rtn4) markers of
kidney injury was veriﬁed by relative real-time RT-PCR on the
tissue from three randomly selected animals from each
experimental group (Table 4). This analysis conﬁrmed the
up- and downregulation of all the selected genes.
DISCUSSION
Vancomycin nephrotoxicity has been reported in humans in
7–17% of cases of MRSA infection treated with this antibiotic
TABLE 4
Relative Real-time RT-PCR Measurements
a compared with Microarray Data (Evaluation Performed on Day 8)
Gene symbol
Vancomycin administration route (dose in mg/kg)
iv-50 iv-200 iv-400 ip-50 ip-200 ip-400
A. Complement pathway and inﬂammation
C3 1 ± 0 (0.8 ± 0.3)
b 6 ± 4 (3.5 ± 2.2) 16 ± 7 (9.2 ± 3.4) 1 ± 0 (0.7 ± 0.2) 1 ± 0 (0.7 ± 0.2) 29 ± 11 (12 ± 3)
C4b 1 ± 0 (0.8 ± 0.1) 10 ± 9( 6± 6) 20 ± 4 (12 ± 4) 1 ± 0( 1± 0.2) 1 ± 0( 1± 0.2) 26 ± 4 (15 ± 5)
Cxcl1 0 ± 0 (N/A) 2 ± 2 (N/A) 10 ± 6 (N/A) 1 ± 0 (N/A) 1 ± 0 (N/A) 190 ± 94 (N/A)
B. Potential biomarkers
Spp1 1 ± 0 (0.8 ± 0.1) 14 ± 12 (1.5 ± 0.4) 31 ± 16 (1.6 ± 0.2) 1 ± 0( 1± 0.1) 1 ± 0( 1± 0.1) 32 ± 3 (1.6 ± 0.1)
Havcr1 1 ± 0 (0.4 ± 0) 11 ± 10 (3.8 ± 0.5) 22 ± 13 (9 ± 3.2) 1 ± 1 (0.7 ± 0) 3 ± 1 (1.1 ± 0.1) 23 ± 5 (7.8 ± 1.8)
Rtn4 0.8 ± 0 (0.8 ± 0.1) 1.8 ± 0.6 (1.3 ± 0.2) 3.4 ± 1 (2.3 ± 0.4) 1.2 ± 0.2 (0.9 ± 0.1) 1.3 ± 0.1 (0.9 ± 0) 5.8 ± 2.5 (2.8 ± 0.8)
aFold expression change relative to the appropriate control samples (iv-0 or ip-0). Results are the average ± SD of the measurements obtained from three animals
per experimental group.
bNumber in parentheses are the average normalized intensity value obtained by microarray ± SD (n ¼ 6). N/A: not available.
264 DIETERICH ET AL.(Downs et al., 1989; Eng et al., 1989; Mellor et al., 1985),
although the mechanisms of toxicity are unclear. We used
a genomic approach to obtain a global view of the
transcriptional response in the kidneys of vancomycin-treated
BALB/c mice and gain insights into the molecular mechanisms
of vancomycin-induced kidney injury. Our study indicated
involvement of oxidative stress and mitochondrial damage in
vancomycin-induced kidney injury. Most importantly, our
study revealed, for the ﬁrst time, a potential contribution of
complement pathway and inﬂammation in the vancomycin-
induced renal toxicity. Expression of several previously
identiﬁed gene-based markers of toxicity was dramatically
affected by administration of high-dose vancomycin. Other
genes presented a dose response to vancomycin and might be
useful as potential biomarkers.
Two routes of administration were used: iv and ip. To our
knowledge, our work is the ﬁrst detailed comparison, at the
genomic level, of responses after iv administration of
vancomycin (clinical use) and ip administration (the most
common route in animal studies). The doses selected in this
study (50, 200, and 400 mg/kg) were extrapolated from the
human dosage to mice; the recommended clinical dose of
30 mg/kg (~2 g/day for an average 70 kg person) in humans
would correspond to a dose of 370 mg/kg in mice according to
surface area conversion. After iv administration in human, Cmax
range from 20 to 50 lg/ml (Palmer-Toy, 2000) which also
correspond to the therapeutic range (Rybak, 2006). Patients
with signs of nephrotoxicity after vancomycin administration
however had Cmax values in the above range (Downs et al.,
1989; Eng et al., 1989; Mellor et al., 1985), supporting the lack
of evidence between pharmacodynamic parameters and overall
patient outcome (Lee et al., 2007; Rybak, 2006).
Globalgeneexpressionproﬁlingofthe kidneyofvancomycin-
treated mice revealed thatsamples clustered according to severity
ofpathology.Samplesfromanimalstreatedivandipat400mg/kg
displayed similar gene expression proﬁles that clustered tightly
together, separately from those of control and low dose groups.
Clustering of the samples from animals treated at the high dose
alsocorrelatedwiththeseverenecrosisoftheproximaltubulesand
signiﬁcant alterations of serum chemistry parameters such as
BUN. Samples from animals treated iv at 200 mg/kg clustered
with samples from the high-dose treatment groups, although the
animals exhibited no clinical signs of toxicity, but samples from
the ip-200 dose group clustered with those from the control
groups. This ﬁnding suggests that gene expression proﬁles
represent an earlier marker for kidney injury than histopathology
and clinicalchemistry,consistentwith knowledgethatchanges in
expression of mRNA in the injured kidney cells are among the
TABLE 5
Normalized Intensity Value of the 12 Oxidative Stress Genes Modiﬁed by at Least Twofold after High-Dose Vancomycin compared
with Control Treatment (Evaluation Performed at Day 8)
Gene symbol Affymetrix ID Genbank iv-0
a iv-400
b ip-0
a ip-400
b
Downregulated genes
Aass1 423523_at BF687395 1.0 ± 0.3 0.4 ± 0.2 1.3 ± 0.1 0.3 ± 0.2
Cat 1416430_at NM_009804 1.1 ± 0.2 0.4 ± 0.2 1.2 ± 0.1 0.4 ± 0.1
1416429_a_at NM_009804 1.0 ± 0.1 0.4 ± 0.1 1.3 ± 0.2 0.5 ± 0.2
Ccs 1448615_at AF173379 1.2 ± 0.3 0.6 ± 0.2 1.0 ± 0.1 0.4 ± 0.1
Fmo2 1422905_s_at NM_018881 1.2 ± 0.3 0.4 ± 0.2 1.5 ± 0.5 0.3 ± 0.2
1453435_a_at AK009753 1.0 ± 0.2 0.3 ± 0.1 1.2 ± 0.2 0.3 ± 0.1
1422904_at NM_018881 1.2 ± 0.4 0.5 ± 0.2 1.4 ± 0.7 0.3 ± 0.2
1435459_at BM936480 0.9 ± 0.2 0.3 ± 0.1 1.1 ± 0.1 0.3 ± 0.1
Gpx6 1452135_at AV001252 1.3 ± 0.4 0.2 ± 0.2 1.0 ± 0.3 0.1 ± 0.0
Gstk1 1452823_at AK002661 1.0 ± 0.2 0.3 ± 0.1 1.1 ± 0.1 0.2 ± 0.1
Nox4 1451827_a_at BC021378 1.0 ± 0.1 0.3 ± 0.1 1.2 ± 0.2 0.2 ± 0.1
1419161_a_at AB041034 1.0 ± 0.3 0.4 ± 0.2 1.3 ± 0.3 0.3 ± 0.2
Scd1 1415965_at NM_009127 1.4 ± 0.4 0.2 ± 0.1 1.5 ± 0.4 0.3 ± 0.2
1415964_at NM_009127 1.2 ± 0.2 0.2 ± 0.1 1.1 ± 0.2 0.1 ± 0.1
Sod2 1444531_at AI847438 1.0 ± 0.1 0.3 ± 0.1 1.3 ± 0.2 0.5 ± 0.1
1454976_at BQ174944 1.1 ± 0.1 0.4 ± 0.1 1.1 ± 0.1 0.4 ± 0.1
Sod3 1417633_at NM_011435 1.2 ± 0.4 0.6 ± 0.3 1.1 ± 0.1 0.4 ± 0.1
Upregulated genes
2310016C16Rik 1424099_at BC019664 0.9 ± 0.2 1.9 ± 0.3 0.9 ± 0.1 2.0 ± 0.3
Vim 1438118_x_at AV147875 0.7 ± 0.2 3.6 ± 0.8 0.9 ± 0.1 5.7 ± 1.3
1450641_at M24849 0.8 ± 0.3 4.6 ± 0.5 0.7 ± 0.1 5.4 ± 1.5
1456292_a_at AV147875 0.7 ± 0.3 4.6 ± 1.6 0.8 ± 0.2 7.0 ± 1.6
aiv-0 and ip-0 represent iv and ip treatment with saline solution.
biv-400 and ip-400 represent iv and ip treatment with vancomycin at 400 mg/kg. Numbers presented in the table are the average normalized intensity value ± SD
(n ¼ 6).
VANCOMYCIN TOXICITY ASSESSED BY MICROARRAY 265earliest events accompanying renal injury (Amin et al.,2 0 0 4 ) .I n
addition,ivandipadministrationof200mg/kgdoseshaddifferent
effects on the host gene transcription proﬁles. Because the Cmax
and the AUC
0/N were 3.4- and 1.7-fold higher after iv
administration of vancomycin at 200 mg/kg than after ip
administration of that dose, our hypothesis is that the Cmax or
AUC
0/N may need to reach a certain threshold before the gene
expressionresponseisaffectedandtoxiceffectsareobserved.This
thresholdwouldbereachedafteradministrationofiv-400,ip-400,
and iv-200, but not ip-200, and this pattern indicates that the
different gene expression proﬁles observed after iv and ip
administration are likely to be associated with different levels of
drug exposure. Our work thus indicates the importance of
considering TK data in interpreting the results of genomics
analysis.
As the major site for renal reabsorption, the proximal tubule
epithelium is rich in transporters and transport mechanisms that
contribute to drug clearance (Lee et al., 2004). After iv and ip
administration of high-dose vancomycin, the expression levels
of several transport-related genes (several Slc, Aqp11, and
Kcnk1) and genes involved in mitochondrial membrane and
envelope (Acad9, Acad10, Acad11, Acadsb, Car5a, Bcat2,
Acaa2, Shmt2, and Sod2) were signiﬁcantly downregulated.
These results suggested that vancomycin altered the energy-
dependent renal reabsorption function of the proximal tubule
cells, consistent with the observation that vancomycin might
alter mitochondrial function (King et al., 2004) and the fact that
the basic mechanism of vancomycin nephrotoxicity depends on
an energy-dependent transport process from the blood to the
tubular cells across the basolateral membrane (Fanos et al.,
2001). Pronounced downregulation of the expression of several
transporters during tubular necrosis was observed in rats after
treatment with various nephrotoxic drugs (Thukral et al.,
2005). Like the ﬁndings of the Thukral et al. study, the
reduction observed in our study may have resulted from loss of
tubular epithelial cells during necrosis, from generalized
downregulation of transport mechanism, or from a combination
of both. Damage to the energy-producing mitochondria was
also indirectly suggested by increased expression of genes
encoding lysosomal proteins such as cathepsins (Ctss, Ctsd,
Ctsc, and Ctsl; Supplementary Table 2) that degrade the worn
out organelles such as mitochondria.
Mitochondria represent a major site of ROS production.
Oxidative stress might be involved in the pathogenesis of
vancomycin-induced nephrotoxicity (Nishino et al., 2002, 2003;
Oktem et al., 2005), observations supported by the potential
protective effects of several antioxidants (Celik et al.,2 0 0 5 ;
Cetin et al., 2007). Our microarray analysis revealed that high-
dose vancomycin upregulated the expression level of Hmox1,a n
indicator of cellular oxidative stress (Abraham et al.,2 0 0 7 ) ,a n d
downregulated the expression level of Cat, Gpx6, Gstk1, Sod2,
and Sod3, which encode some of the main cellular antioxidants
(Scandalios, 2005). Our observations correlated with the reduced
antioxidant activity (super oxide dismutase, catalasse) in the
kidney of vancomycin-treated rats (Cetin et al., 2007; Oktem
et al., 2005). Depletion of genes protecting from oxidative stress
was also observed in ochratoxin A–treated rats (Marin-Kuan
et al., 2006). All together, our results suggest that, by reducing
antioxidant activity, vancomycin might increase production of
ROS. Oxidative stress dysfunction might be responsible, at least
partly, for the development of the observed tubular necrosis.
Even though apoptosis and necrosis are often preceded by
mitochondrial dysfunction (Lemasters et al., 1999), we cannot
rule out the possibility that the oxidative stress response might
represent a secondary by-product of necrosis.
FIG. 4. Expression level of the gene-based markers of nephrotoxicity.
Graph represents the expression level of 15 of the previously identiﬁed gene
markers of nephrotoxicity (Amin et al., 2004) after administration of high-dose
vancomycin via the iv (iv-400) and ip (ip-400) routes or administration of
saline (iv-0 and ip-0). Expression levels are presented as the Log2 of the
average (n ¼ 6) normalized intensity value.
266 DIETERICH ET AL.In addition to necrosis, signs of tissue repair were also
detected in vancomycin-treated animals. First, we observed
regeneration of cuboidal cells. Second, there was strong
upregulation of nine transcripts encoding procollagen genes,
including Col4a1 and Col4a2; collagen IV promote repair of
renal cell physiological functions after toxicant injury (Nony
et al., 2001). Tissue repair was also suggested by upregulation
of cell cycle genes (Cdk6, Cdkn1a,a n dCdkn2d, see
Supplementary Table 2), and of Vim (Table 5). Vim encodes
vimentin, an intermediate ﬁlament protein that might restore
transport activity in injured kidneys (Runembert et al., 2004).
These observations are consistent with the proliferation
observed following vancomycin treatment in renal proximal
tubule epithelial cells (King et al., 2004).
Analysis of the overall kidney gene expression response for
signiﬁcantly enriched GO pathways revealed that several
components of the complement pathway, as well as chemo-
kines, were strongly upregulated after iv and ip administration
of high-dose vancomycin. Renal I/R is a common cause of
acute renal failure, recently renamed acute kidney injury
(Vaidya et al., 2008); it triggers a robust inﬂammatory response
and activates the complement system, both of which sub-
sequently contribute to the resulting tissue injury (Thurman,
2007). The complement pathway is not only associated with
damages after renal I/R, it is also an important mediator of local
tissue injury in the kidney (Sheerin et al., 2008). We thus
speculated that vancomycin-induced kidney injury may also be
mediated by complement activation and development of an
inﬂammatory response. Using relative real-time RT-PCR, we
conﬁrmed the increased expression of some of the complement
genes (C3 and C4b); we also identiﬁed increased expression of
Cxcl1, an early biomarker of ischemic acute renal failure
(Molls et al., 2006). Cxcl1 is produced in a complement-
dependent fashion, suggesting that complement activation
mediates tissue inﬂammation through the generation of such
a factor (Thurman et al., 2007). This result might contrast with
the minimal inﬂammatory cell inﬁltration observed. However,
because changes in expression of mRNA in the injured kidney
cells are among the earliest events accompanying renal injury
(Amin et al., 2004), microscopic tissue changes might only be
detectable at later time points.
This study is the ﬁrst to report that vancomycin-induced
gene expression changes are enriched in the inﬂammation and
complement pathway response, suggesting a link between
vancomycin-induced nephrotoxicity and complement activa-
tion. Further work will be required to elucidate the role of the
complement pathway in vancomycin-induced nephrotoxicity; it
would be useful, for example, to analyze the deposition of C3
along the tubular membrane (Thurman, 2007) or the vanco-
mycin response of complement-deﬁcient mice using an
approach similar to that of Thurman et al. (2003).
Several genes have been described as potential signatures for
drug-induced kidney injury, especially KIM-1/Havcr1
(Han et al., 2002; Ichimura et al., 1998). Other genes,
including Spp1 and Clu, are upregulated in the kidney of rats
(Amin et al., 2004; Kharasch et al., 2006; Thompson et al.,
2004) and primates (Davis et al., 2004), and wider use of these
genes as markers has been suggested.
Administration of high-dose vancomycin upregulated the
expression of Havcr1, Spp1,a n dClu, substantiating the use of
these markers as an indicator of renal injury. The induction of
mRNA transcript for Havcr1 and Spp1 was conﬁrmed by
relative real-time RT-PCR. Several other potential biomarkers
include L-arginine-glycine amidinotransferase (Gatm)a n d
guanidinoacetate methyltransferase (Gamt) (Amin et al.,2 0 0 4 ;
Kharasch et al., 2006; Thompson et al., 2004), both key players
in the CRE biosynthesis pathway. Although we did not observe
changes in serum levels of CRE, vancomycin treatment
downregulated the expression of these two genes (Gatm and
Gamt), suggesting dysregulation of the CRE pathway.
Finally, our microarray analysis identiﬁed four genes whose
expression proﬁles changed gradually as iv dose levels of
vancomycin increased: Sprr1a, AI606844, Rtn4, and Arl4d.
The relevance of these genes in kidney injury is unknown.
However, markers do not always have known functional
relevance; in the Fielden study for example, 37% (13/35) of the
genes predicting the future onset of drug-induced renal tubular
toxicity were expressed sequence tags with no similarities to
other known genes (Fielden et al., 2005).
Future studies will be required to conﬁrm the change in
expression level of these potential gene markers and to determine
whether these changes can be identiﬁed after brief exposure to
vancomycin, before the onset of clinical signs of toxicity.
Because vancomycin is not administered to healthy individuals,
there is a need to evaluate whether these markers could be
identiﬁable in the context of an infection such as MRSA. If so,
they could make a major contribution to the application of
toxicogenomics to clinical medicine. Our work represents the
ﬁrst step toward this goal and provides information on novel
mechanisms of vancomycin-induced kidney injury that might be
critical in devising ways to prevent toxicity in patients.
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